Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Originalsprog | Engelsk |
---|---|
Tidsskrift | The Lancet Haematology |
Vol/bind | 10 |
Udgave nummer | 8 |
Sider (fra-til) | e687-e694 |
Antal sider | 8 |
ISSN | 2352-3026 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
We thank Anne Sophie Adam, Patrick Ducoroy, Bichr Allaf, Ana Marcao, and Marelle Bouva for gathering information about the status of national neonatal screening programmes on sickle cell disease ERN-EuroBloodNet actions are carried out thanks to the European Reference Network on Rare Haematological Diseases members and European patient advocacy groups. ERN-EuroBloodNet is partly funded by the EU within the framework of the Fourth EU Health Programme (ERN-EuroBloodNet GA101085717). ENROL is cofunded by the European Commission—Consumers, Health, Agriculture and Food Executive Agency under the call for proposals HPPJ-2019 on Rare Disease Registries for the European Reference Networks (ENROL GA947670). Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps.
Funding Information:
We thank Anne Sophie Adam, Patrick Ducoroy, Bichr Allaf, Ana Marcao, and Marelle Bouva for gathering information about the status of national neonatal screening programmes on sickle cell disease ERN-EuroBloodNet actions are carried out thanks to the European Reference Network on Rare Haematological Diseases members and European patient advocacy groups. ERN-EuroBloodNet is partly funded by the EU within the framework of the Fourth EU Health Programme (ERN-EuroBloodNet GA101085717). ENROL is cofunded by the European Commission—Consumers, Health, Agriculture and Food Executive Agency under the call for proposals HPPJ-2019 on Rare Disease Registries for the European Reference Networks (ENROL GA947670).
Publisher Copyright:
© 2023 Elsevier Ltd
ID: 397756329